Enliven Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

ELVN$51.20-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance - January 1, 2025	48,936,459	$49	$553,213	$55	$(243,472)	$309,845
Exercise of common stock options	91,915	—	234	—	—	234
Vesting of restricted stock units	10,356	—	—	—	—	—
Vesting of stock options	—	—	33	—	—	33
Stock-based compensation	—	—	6,799	—	—	6,799
Net loss	—	—	—	—	(28,544)	(28,544)
Other comprehensive loss	—	—	—	(71)	—	(71)
Balance - March 31, 2025	49,038,730	$49	$560,279	$(16)	$(272,016)	$288,296
Exercise of common stock options	236,893	—	1,324	—	—	1,324
Vesting of restricted stock units	6,604	—	—	—	—	—
Vesting of stock options	—	—	28	—	—	28
Issuance of common stock under the ESPP	22,957	—	427	—	—	427
Issuance of common stock and pre-funded warrants in the 2025 Public Offering, net of issuance costs of $13,875	9,920,987	10	216,159	—	—	216,169
Stock-based compensation	—	—	7,724	—	—	7,724
Net loss	—	—	—	—	(25,335)	(25,335)
Other comprehensive loss	—	—	—	(161)	—	(161)
Balance - June 30, 2025	59,226,171	$59	$785,941	$(177)	$(297,351)	$488,472
Exercise of common stock options	28,507	—	209	—	—	209
Vesting of restricted stock units	6,608	—	—	—	—	—
Vesting of stock options	—	—	6	—	—	6
Stock-based compensation	—	—	7,185	—	—	7,185
Net loss	—	—	—	—	(20,148)	(20,148)
Other comprehensive income	—	—	—	398	—	398
Balance - September 30, 2025	59,261,286	$59	$793,341	$221	$(317,499)	$476,122

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

Common Stock · Additional Paid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance - January 1, 2026	59,440,045	$59	$806,373	$334	$(347,166)	$459,600
Exercise of common stock options	1,435,253	2	10,709	—	—	10,711
Vesting of restricted stock units	14,357	—	—	—	—	—
Stock-based compensation	—	—	7,397	—	—	7,397
Net loss	—	—	—	—	(23,627)	(23,627)
Other comprehensive loss	—	—	—	(716)	—	(716)
Balance - March 31, 2026	60,889,655	$61	$824,479	$(382)	$(370,793)	$453,365
Exercise of common stock options	1,795,854	1	28,928	—	—	28,929
Vesting of restricted stock units	8,541	—	—	—	—	—
Issuance of common stock under the ESPP	24,264	—	354	—	—	354
Issuance of common stock and pre-funded warrants in the 2026 Public Offering, net of issuance costs of $27,405	10,533,334	11	432,583	—	—	432,594
Stock-based compensation	—	—	13,915	—	—	13,915
Net loss	—	—	—	—	(32,485)	(32,485)
Other comprehensive loss	—	—	—	(1,523)	—	(1,523)
Balance - June 30, 2026	73,251,648	$73	$1,300,259	$(1,905)	$(403,278)	$895,149
Exercise of common stock options	297,175	1	3,052	—	—	3,053
Vesting of restricted stock units	8,546	—	—	—	—	—
Stock-based compensation	—	—	8,056	—	—	8,056
Net loss	—	—	—	—	(27,703)	(27,703)
Other comprehensive loss	—	—	—	(1,608)	—	(1,608)
Balance - September 30, 2026	73,557,369	$74	$1,311,367	$(3,513)	$(430,981)	$876,947

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.